Technical analysis of Ascendis Pharma A/S (ASND): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
Price Performance
| 1 month | +9.19% |
| 3 months | -0.35% |
| Year-to-date | +16.76% |
| 1 year | +19.56% |
| 3 years | +163.05% |
| 5 years | +54.95% |
| 10 years | +1193.40% |
52-Week Range
| 52-week High | $282.15 |
| 52-week Low | $188.07 |
| Avg Volume (90d) | 699K |
Technical Indicators
| SMA 50 | $242.22 |
| SMA 200 | $238.27 |
| Beta | 0.48 |
| 30-day Volatility (annualised) | 29.5% |
| Price vs SMA 50 | +2.8% |
| Price vs SMA 200 | +4.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $213.24 | |
| 2026-01 | $226.10 | +6.0% |
| 2026-02 | $233.50 | +3.3% |
| 2026-03 | $228.73 | -2.0% |
| 2026-04 | $229.38 | +0.3% |
| 2026-05 | $224.11 | -2.3% |
| 2026-06 | $266.72 | +19.0% |
| 2026-07 | $243.91 | -8.6% |
| 2026-08 | $263.04 | +7.8% |
| 2026-09 | $227.83 | -13.4% |
| 2026-10 | $251.27 | +10.3% |
| 2026-11 | $248.98 | -0.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-11 | $0.89 | $409M |
| 2026-08-13 | $1.71 | $377M |
| 2026-05-07 | $0.19 | $309M |
| 2026-02-11 | $-0.06 | $292M |
| 2025-11-12 | $-0.41 | $303M |
| 2025-08-07 | $-1.42 | $233M |
| 2025-05-01 | $-1.56 | $153M |
Price
| Price | $250.17 (closing price, November 3, 2026) |
| Market Cap | $16.5B |
| Exchange | NASDAQ |
| Country | DK |
Valuation Ratios
| P/E Ratio | 18.46 |
| Price / Book | 10.01 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.31 |
| Current Ratio | 2.99 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.84 |